Pifeltro

Active Ingredient(s): Doravirine
FDA Approved: * August 30, 2018
Pharm Company: * MSD MERCK CO
Category: HIV / AIDS

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Pifeltro Overview

Doravirine, sold under the brand name Pifeltro, is a non-nucleoside reverse transcriptase inhibitor medication developed by Merck & Co. for use in the treatment of HIV/AIDS. Doravirine was approved for medical use in the United States in August 2018.[5] References .mw-parser-output .reflist{font-size:90%;margin-bottom:0.5em;list-style-type:decimal}.mw-parser-output .reflist .references{font-size:100%;margin-bottom:0;list-style-type:inherit}.mw-parser-output .reflist-col...

Read more Pifeltro Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Doravirine

Recent Pifeltro Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Doravirine
  • Tablet: 100mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Pifeltro: (1 result)

Sorted by National Drug Code
  • 0006-3069 Pifeltro 100 mg Oral Tablet, Film Coated by Merck Sharp & Dohme Corp.

Other drugs which contain Doravirine or a similar ingredient: (3 results)